FDA approves biosimilar competitor to Amgen’s Enbrel
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Oliver: Slow revolving door of mental illness, addiction, incarceration
By Malcolm Oliver, Alexis Villegas and Crawford Coats The Centers for Disease Control and Prevention report that alcohol, drugs and suicide claimed more than 150,000 lives in 2018. To put this number into perspective, that’s more than twice the number of American soldiers killed in Vietnam. The Central Coast is not immune to the revolving Read More →
Disruption ahead for health care in the Tri-Counties
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s Evenity osteoporosis treatment priced at $21,900 per year
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Street Smarts: Gold Coast Recycling wants to bring U.S. markets back
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dubroff: Boeing taps Amgen’s Bradway to navigate 737 MAX mess
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen gets FDA approval for osteoporosis drug Evenity
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
